Global New Molecular Entities (NME) Drugs Market Growth 2026-2032
The global New Molecular Entities (NME) Drugs market size is predicted to grow from US$ 230306 million in 2025 to US$ 372890 million in 2032; it is expected to grow at a CAGR of 7.1% from 2026 to 2032.
In 2025, global New Molecular Entities (NME) Drugs reached approximately 96.94 M Units, with an average global market price of around 2428 USD per Unit.
New Molecular Entity (NME) drugs are pharmaceutical products that contain an active ingredient never before approved by the U.S. Food and Drug Administration (FDA) or other major regulatory authorities for use in humans. An NME is characterized by a novel chemical structure or molecular composition, meaning the active substance has not previously been marketed or authorized in any drug product. NMEs represent true pharmaceutical innovation, as they introduce new mechanisms of action, new biological targets, or new therapeutic approaches for the prevention, diagnosis, or treatment of disease. They are typically approved by the FDA under a New Drug Application (NDA) (for small-molecule drugs) and are closely tracked by regulators and the pharmaceutical industry as a key indicator of research and development (R&D) productivity and innovation strength.
The upstream raw materials for new molecular entity (NME) drugs mainly include active pharmaceutical ingredients (APIs), pharmaceutical intermediates, excipients, etc. Typical suppliers include Pfizer, Roche, Merck, AstraZeneca, etc. The downstream applications are mainly in the treatment of oncology, immune diseases, cardiovascular diseases, etc.
The single-line production capacity of new molecular entity (NME) drugs varies greatly depending on the type of drug molecule, process complexity, equipment scale and production mode, and the industry gross profit margin is usually in the range of 60%-80%.
United States market for New Molecular Entities (NME) Drugs is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for New Molecular Entities (NME) Drugs is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for New Molecular Entities (NME) Drugs is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key New Molecular Entities (NME) Drugs players cover Roche, Novartis, Merck, Pfizer, AstraZeneca, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LP Information, Inc. (LPI) ' newest research report, the “New Molecular Entities (NME) Drugs Industry Forecast” looks at past sales and reviews total world New Molecular Entities (NME) Drugs sales in 2025, providing a comprehensive analysis by region and market sector of projected New Molecular Entities (NME) Drugs sales for 2026 through 2032. With New Molecular Entities (NME) Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world New Molecular Entities (NME) Drugs industry.
This Insight Report provides a comprehensive analysis of the global New Molecular Entities (NME) Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on New Molecular Entities (NME) Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global New Molecular Entities (NME) Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for New Molecular Entities (NME) Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global New Molecular Entities (NME) Drugs.
This report presents a comprehensive overview, market shares, and growth opportunities of New Molecular Entities (NME) Drugs market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
In 2025, global New Molecular Entities (NME) Drugs reached approximately 96.94 M Units, with an average global market price of around 2428 USD per Unit.
New Molecular Entity (NME) drugs are pharmaceutical products that contain an active ingredient never before approved by the U.S. Food and Drug Administration (FDA) or other major regulatory authorities for use in humans. An NME is characterized by a novel chemical structure or molecular composition, meaning the active substance has not previously been marketed or authorized in any drug product. NMEs represent true pharmaceutical innovation, as they introduce new mechanisms of action, new biological targets, or new therapeutic approaches for the prevention, diagnosis, or treatment of disease. They are typically approved by the FDA under a New Drug Application (NDA) (for small-molecule drugs) and are closely tracked by regulators and the pharmaceutical industry as a key indicator of research and development (R&D) productivity and innovation strength.
The upstream raw materials for new molecular entity (NME) drugs mainly include active pharmaceutical ingredients (APIs), pharmaceutical intermediates, excipients, etc. Typical suppliers include Pfizer, Roche, Merck, AstraZeneca, etc. The downstream applications are mainly in the treatment of oncology, immune diseases, cardiovascular diseases, etc.
The single-line production capacity of new molecular entity (NME) drugs varies greatly depending on the type of drug molecule, process complexity, equipment scale and production mode, and the industry gross profit margin is usually in the range of 60%-80%.
United States market for New Molecular Entities (NME) Drugs is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for New Molecular Entities (NME) Drugs is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for New Molecular Entities (NME) Drugs is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key New Molecular Entities (NME) Drugs players cover Roche, Novartis, Merck, Pfizer, AstraZeneca, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LP Information, Inc. (LPI) ' newest research report, the “New Molecular Entities (NME) Drugs Industry Forecast” looks at past sales and reviews total world New Molecular Entities (NME) Drugs sales in 2025, providing a comprehensive analysis by region and market sector of projected New Molecular Entities (NME) Drugs sales for 2026 through 2032. With New Molecular Entities (NME) Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world New Molecular Entities (NME) Drugs industry.
This Insight Report provides a comprehensive analysis of the global New Molecular Entities (NME) Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on New Molecular Entities (NME) Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global New Molecular Entities (NME) Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for New Molecular Entities (NME) Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global New Molecular Entities (NME) Drugs.
This report presents a comprehensive overview, market shares, and growth opportunities of New Molecular Entities (NME) Drugs market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Small Molecules
- Monoclonal Antibodies
- ADCs
- Others
- Oral Drugs
- Injectable Drugs
- Others
- Receptor Agonists
- Enzyme Inhibitors
- Others
- Cancer Diseases
- Immune Diseases
- Cardiovascular Diseases
- Others
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Roche
- Novartis
- Merck
- Pfizer
- AstraZeneca
- Johnson & Johnson
- Bristol Myers Squibb
- Bayer
- GSK
- Daiichi Sankyo
- Amgen
- Eli Lilly and Company
- AbbVie
- Sanofi
- Takeda
- Boehringer Ingelheim
- Beigene, Ltd.
- Jiangsu Hengrui Medicine
- INNOVENT BIOLOGICS(SUZHOU)
- Betta Pharmaceuticals
- Remegen Co.,Ltd.
- Shanghai Allist Pharmaceuticals
- Innocare
- Huiyu Pharmaceuticals
- What is the 10-year outlook for the global New Molecular Entities (NME) Drugs market?
- What factors are driving New Molecular Entities (NME) Drugs market growth, globally and by region?
- Which technologies are poised for the fastest growth by market and region?
- How do New Molecular Entities (NME) Drugs market opportunities vary by end market size?
- How does New Molecular Entities (NME) Drugs break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global New Molecular Entities (NME) Drugs Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for New Molecular Entities (NME) Drugs by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for New Molecular Entities (NME) Drugs by Country/Region, 2021, 2025 & 2032
2.2 New Molecular Entities (NME) Drugs Segment by Type
2.2.1 Small Molecules
2.2.2 Monoclonal Antibodies
2.2.3 ADCs
2.2.4 Others
2.2.5 New Molecular Entities (NME) Drugs Sales by Type
2.2.5.1 Global New Molecular Entities (NME) Drugs Sales Market Share by Type (2021-2026)
2.2.5.2 Global New Molecular Entities (NME) Drugs Revenue and Market Share by Type (2021-2026)
2.2.5.3 Global New Molecular Entities (NME) Drugs Sale Price by Type (2021-2026)
2.3 New Molecular Entities (NME) Drugs Segment by Administration Route
2.3.1 Oral Drugs
2.3.2 Injectable Drugs
2.3.3 Others
2.3.4 New Molecular Entities (NME) Drugs Sales by Administration Route
2.3.4.1 Global New Molecular Entities (NME) Drugs Sales Market Share by Administration Route (2021-2026)
2.3.4.2 Global New Molecular Entities (NME) Drugs Revenue and Market Share by Administration Route (2021-2026)
2.3.4.3 Global New Molecular Entities (NME) Drugs Sale Price by Administration Route (2021-2026)
2.4 New Molecular Entities (NME) Drugs Segment by Action Mechanism
2.4.1 Receptor Agonists
2.4.2 Enzyme Inhibitors
2.4.3 Others
2.4.4 New Molecular Entities (NME) Drugs Sales by Action Mechanism
2.4.4.1 Global New Molecular Entities (NME) Drugs Sales Market Share by Action Mechanism (2021-2026)
2.4.4.2 Global New Molecular Entities (NME) Drugs Revenue and Market Share by Action Mechanism (2021-2026)
2.4.4.3 Global New Molecular Entities (NME) Drugs Sale Price by Action Mechanism (2021-2026)
2.5 New Molecular Entities (NME) Drugs Segment by Application
2.5.1 Cancer Diseases
2.5.2 Immune Diseases
2.5.3 Cardiovascular Diseases
2.5.4 Others
2.5.5 New Molecular Entities (NME) Drugs Sales by Application
2.5.5.1 Global New Molecular Entities (NME) Drugs Sale Market Share by Application (2021-2026)
2.5.5.2 Global New Molecular Entities (NME) Drugs Revenue and Market Share by Application (2021-2026)
2.5.5.3 Global New Molecular Entities (NME) Drugs Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global New Molecular Entities (NME) Drugs Breakdown Data by Company
3.1.1 Global New Molecular Entities (NME) Drugs Annual Sales by Company (2021-2026)
3.1.2 Global New Molecular Entities (NME) Drugs Sales Market Share by Company (2021-2026)
3.2 Global New Molecular Entities (NME) Drugs Annual Revenue by Company (2021-2026)
3.2.1 Global New Molecular Entities (NME) Drugs Revenue by Company (2021-2026)
3.2.2 Global New Molecular Entities (NME) Drugs Revenue Market Share by Company (2021-2026)
3.3 Global New Molecular Entities (NME) Drugs Sale Price by Company
3.4 Key Manufacturers New Molecular Entities (NME) Drugs Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers New Molecular Entities (NME) Drugs Product Location Distribution
3.4.2 Players New Molecular Entities (NME) Drugs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR NEW MOLECULAR ENTITIES (NME) DRUGS BY GEOGRAPHIC REGION
4.1 World Historic New Molecular Entities (NME) Drugs Market Size by Geographic Region (2021-2026)
4.1.1 Global New Molecular Entities (NME) Drugs Annual Sales by Geographic Region (2021-2026)
4.1.2 Global New Molecular Entities (NME) Drugs Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic New Molecular Entities (NME) Drugs Market Size by Country/Region (2021-2026)
4.2.1 Global New Molecular Entities (NME) Drugs Annual Sales by Country/Region (2021-2026)
4.2.2 Global New Molecular Entities (NME) Drugs Annual Revenue by Country/Region (2021-2026)
4.3 Americas New Molecular Entities (NME) Drugs Sales Growth
4.4 APAC New Molecular Entities (NME) Drugs Sales Growth
4.5 Europe New Molecular Entities (NME) Drugs Sales Growth
4.6 Middle East & Africa New Molecular Entities (NME) Drugs Sales Growth
5 AMERICAS
5.1 Americas New Molecular Entities (NME) Drugs Sales by Country
5.1.1 Americas New Molecular Entities (NME) Drugs Sales by Country (2021-2026)
5.1.2 Americas New Molecular Entities (NME) Drugs Revenue by Country (2021-2026)
5.2 Americas New Molecular Entities (NME) Drugs Sales by Type (2021-2026)
5.3 Americas New Molecular Entities (NME) Drugs Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC New Molecular Entities (NME) Drugs Sales by Region
6.1.1 APAC New Molecular Entities (NME) Drugs Sales by Region (2021-2026)
6.1.2 APAC New Molecular Entities (NME) Drugs Revenue by Region (2021-2026)
6.2 APAC New Molecular Entities (NME) Drugs Sales by Type (2021-2026)
6.3 APAC New Molecular Entities (NME) Drugs Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe New Molecular Entities (NME) Drugs by Country
7.1.1 Europe New Molecular Entities (NME) Drugs Sales by Country (2021-2026)
7.1.2 Europe New Molecular Entities (NME) Drugs Revenue by Country (2021-2026)
7.2 Europe New Molecular Entities (NME) Drugs Sales by Type (2021-2026)
7.3 Europe New Molecular Entities (NME) Drugs Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa New Molecular Entities (NME) Drugs by Country
8.1.1 Middle East & Africa New Molecular Entities (NME) Drugs Sales by Country (2021-2026)
8.1.2 Middle East & Africa New Molecular Entities (NME) Drugs Revenue by Country (2021-2026)
8.2 Middle East & Africa New Molecular Entities (NME) Drugs Sales by Type (2021-2026)
8.3 Middle East & Africa New Molecular Entities (NME) Drugs Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of New Molecular Entities (NME) Drugs
10.3 Manufacturing Process Analysis of New Molecular Entities (NME) Drugs
10.4 Industry Chain Structure of New Molecular Entities (NME) Drugs
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 New Molecular Entities (NME) Drugs Distributors
11.3 New Molecular Entities (NME) Drugs Customer
12 WORLD FORECAST REVIEW FOR NEW MOLECULAR ENTITIES (NME) DRUGS BY GEOGRAPHIC REGION
12.1 Global New Molecular Entities (NME) Drugs Market Size Forecast by Region
12.1.1 Global New Molecular Entities (NME) Drugs Forecast by Region (2027-2032)
12.1.2 Global New Molecular Entities (NME) Drugs Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global New Molecular Entities (NME) Drugs Forecast by Type (2027-2032)
12.7 Global New Molecular Entities (NME) Drugs Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Roche
13.1.1 Roche Company Information
13.1.2 Roche New Molecular Entities (NME) Drugs Product Portfolios and Specifications
13.1.3 Roche New Molecular Entities (NME) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Roche Main Business Overview
13.1.5 Roche Latest Developments
13.2 Novartis
13.2.1 Novartis Company Information
13.2.2 Novartis New Molecular Entities (NME) Drugs Product Portfolios and Specifications
13.2.3 Novartis New Molecular Entities (NME) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Novartis Main Business Overview
13.2.5 Novartis Latest Developments
13.3 Merck
13.3.1 Merck Company Information
13.3.2 Merck New Molecular Entities (NME) Drugs Product Portfolios and Specifications
13.3.3 Merck New Molecular Entities (NME) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Merck Main Business Overview
13.3.5 Merck Latest Developments
13.4 Pfizer
13.4.1 Pfizer Company Information
13.4.2 Pfizer New Molecular Entities (NME) Drugs Product Portfolios and Specifications
13.4.3 Pfizer New Molecular Entities (NME) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Pfizer Main Business Overview
13.4.5 Pfizer Latest Developments
13.5 AstraZeneca
13.5.1 AstraZeneca Company Information
13.5.2 AstraZeneca New Molecular Entities (NME) Drugs Product Portfolios and Specifications
13.5.3 AstraZeneca New Molecular Entities (NME) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 AstraZeneca Main Business Overview
13.5.5 AstraZeneca Latest Developments
13.6 Johnson & Johnson
13.6.1 Johnson & Johnson Company Information
13.6.2 Johnson & Johnson New Molecular Entities (NME) Drugs Product Portfolios and Specifications
13.6.3 Johnson & Johnson New Molecular Entities (NME) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Johnson & Johnson Main Business Overview
13.6.5 Johnson & Johnson Latest Developments
13.7 Bristol Myers Squibb
13.7.1 Bristol Myers Squibb Company Information
13.7.2 Bristol Myers Squibb New Molecular Entities (NME) Drugs Product Portfolios and Specifications
13.7.3 Bristol Myers Squibb New Molecular Entities (NME) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Bristol Myers Squibb Main Business Overview
13.7.5 Bristol Myers Squibb Latest Developments
13.8 Bayer
13.8.1 Bayer Company Information
13.8.2 Bayer New Molecular Entities (NME) Drugs Product Portfolios and Specifications
13.8.3 Bayer New Molecular Entities (NME) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Bayer Main Business Overview
13.8.5 Bayer Latest Developments
13.9 GSK
13.9.1 GSK Company Information
13.9.2 GSK New Molecular Entities (NME) Drugs Product Portfolios and Specifications
13.9.3 GSK New Molecular Entities (NME) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 GSK Main Business Overview
13.9.5 GSK Latest Developments
13.10 Daiichi Sankyo
13.10.1 Daiichi Sankyo Company Information
13.10.2 Daiichi Sankyo New Molecular Entities (NME) Drugs Product Portfolios and Specifications
13.10.3 Daiichi Sankyo New Molecular Entities (NME) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 Daiichi Sankyo Main Business Overview
13.10.5 Daiichi Sankyo Latest Developments
13.11 Amgen
13.11.1 Amgen Company Information
13.11.2 Amgen New Molecular Entities (NME) Drugs Product Portfolios and Specifications
13.11.3 Amgen New Molecular Entities (NME) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 Amgen Main Business Overview
13.11.5 Amgen Latest Developments
13.12 Eli Lilly and Company
13.12.1 Eli Lilly and Company Company Information
13.12.2 Eli Lilly and Company New Molecular Entities (NME) Drugs Product Portfolios and Specifications
13.12.3 Eli Lilly and Company New Molecular Entities (NME) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.12.4 Eli Lilly and Company Main Business Overview
13.12.5 Eli Lilly and Company Latest Developments
13.13 AbbVie
13.13.1 AbbVie Company Information
13.13.2 AbbVie New Molecular Entities (NME) Drugs Product Portfolios and Specifications
13.13.3 AbbVie New Molecular Entities (NME) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.13.4 AbbVie Main Business Overview
13.13.5 AbbVie Latest Developments
13.14 Sanofi
13.14.1 Sanofi Company Information
13.14.2 Sanofi New Molecular Entities (NME) Drugs Product Portfolios and Specifications
13.14.3 Sanofi New Molecular Entities (NME) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.14.4 Sanofi Main Business Overview
13.14.5 Sanofi Latest Developments
13.15 Takeda
13.15.1 Takeda Company Information
13.15.2 Takeda New Molecular Entities (NME) Drugs Product Portfolios and Specifications
13.15.3 Takeda New Molecular Entities (NME) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.15.4 Takeda Main Business Overview
13.15.5 Takeda Latest Developments
13.16 Boehringer Ingelheim
13.16.1 Boehringer Ingelheim Company Information
13.16.2 Boehringer Ingelheim New Molecular Entities (NME) Drugs Product Portfolios and Specifications
13.16.3 Boehringer Ingelheim New Molecular Entities (NME) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.16.4 Boehringer Ingelheim Main Business Overview
13.16.5 Boehringer Ingelheim Latest Developments
13.17 Beigene, Ltd.
13.17.1 Beigene, Ltd. Company Information
13.17.2 Beigene, Ltd. New Molecular Entities (NME) Drugs Product Portfolios and Specifications
13.17.3 Beigene, Ltd. New Molecular Entities (NME) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.17.4 Beigene, Ltd. Main Business Overview
13.17.5 Beigene, Ltd. Latest Developments
13.18 Jiangsu Hengrui Medicine
13.18.1 Jiangsu Hengrui Medicine Company Information
13.18.2 Jiangsu Hengrui Medicine New Molecular Entities (NME) Drugs Product Portfolios and Specifications
13.18.3 Jiangsu Hengrui Medicine New Molecular Entities (NME) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.18.4 Jiangsu Hengrui Medicine Main Business Overview
13.18.5 Jiangsu Hengrui Medicine Latest Developments
13.19 INNOVENT BIOLOGICS(SUZHOU)
13.19.1 INNOVENT BIOLOGICS(SUZHOU) Company Information
13.19.2 INNOVENT BIOLOGICS(SUZHOU) New Molecular Entities (NME) Drugs Product Portfolios and Specifications
13.19.3 INNOVENT BIOLOGICS(SUZHOU) New Molecular Entities (NME) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.19.4 INNOVENT BIOLOGICS(SUZHOU) Main Business Overview
13.19.5 INNOVENT BIOLOGICS(SUZHOU) Latest Developments
13.20 Betta Pharmaceuticals
13.20.1 Betta Pharmaceuticals Company Information
13.20.2 Betta Pharmaceuticals New Molecular Entities (NME) Drugs Product Portfolios and Specifications
13.20.3 Betta Pharmaceuticals New Molecular Entities (NME) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.20.4 Betta Pharmaceuticals Main Business Overview
13.20.5 Betta Pharmaceuticals Latest Developments
13.21 Remegen Co.,Ltd.
13.21.1 Remegen Co.,Ltd. Company Information
13.21.2 Remegen Co.,Ltd. New Molecular Entities (NME) Drugs Product Portfolios and Specifications
13.21.3 Remegen Co.,Ltd. New Molecular Entities (NME) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.21.4 Remegen Co.,Ltd. Main Business Overview
13.21.5 Remegen Co.,Ltd. Latest Developments
13.22 Shanghai Allist Pharmaceuticals
13.22.1 Shanghai Allist Pharmaceuticals Company Information
13.22.2 Shanghai Allist Pharmaceuticals New Molecular Entities (NME) Drugs Product Portfolios and Specifications
13.22.3 Shanghai Allist Pharmaceuticals New Molecular Entities (NME) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.22.4 Shanghai Allist Pharmaceuticals Main Business Overview
13.22.5 Shanghai Allist Pharmaceuticals Latest Developments
13.23 Innocare
13.23.1 Innocare Company Information
13.23.2 Innocare New Molecular Entities (NME) Drugs Product Portfolios and Specifications
13.23.3 Innocare New Molecular Entities (NME) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.23.4 Innocare Main Business Overview
13.23.5 Innocare Latest Developments
13.24 Huiyu Pharmaceuticals
13.24.1 Huiyu Pharmaceuticals Company Information
13.24.2 Huiyu Pharmaceuticals New Molecular Entities (NME) Drugs Product Portfolios and Specifications
13.24.3 Huiyu Pharmaceuticals New Molecular Entities (NME) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.24.4 Huiyu Pharmaceuticals Main Business Overview
13.24.5 Huiyu Pharmaceuticals Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global New Molecular Entities (NME) Drugs Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for New Molecular Entities (NME) Drugs by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for New Molecular Entities (NME) Drugs by Country/Region, 2021, 2025 & 2032
2.2 New Molecular Entities (NME) Drugs Segment by Type
2.2.1 Small Molecules
2.2.2 Monoclonal Antibodies
2.2.3 ADCs
2.2.4 Others
2.2.5 New Molecular Entities (NME) Drugs Sales by Type
2.2.5.1 Global New Molecular Entities (NME) Drugs Sales Market Share by Type (2021-2026)
2.2.5.2 Global New Molecular Entities (NME) Drugs Revenue and Market Share by Type (2021-2026)
2.2.5.3 Global New Molecular Entities (NME) Drugs Sale Price by Type (2021-2026)
2.3 New Molecular Entities (NME) Drugs Segment by Administration Route
2.3.1 Oral Drugs
2.3.2 Injectable Drugs
2.3.3 Others
2.3.4 New Molecular Entities (NME) Drugs Sales by Administration Route
2.3.4.1 Global New Molecular Entities (NME) Drugs Sales Market Share by Administration Route (2021-2026)
2.3.4.2 Global New Molecular Entities (NME) Drugs Revenue and Market Share by Administration Route (2021-2026)
2.3.4.3 Global New Molecular Entities (NME) Drugs Sale Price by Administration Route (2021-2026)
2.4 New Molecular Entities (NME) Drugs Segment by Action Mechanism
2.4.1 Receptor Agonists
2.4.2 Enzyme Inhibitors
2.4.3 Others
2.4.4 New Molecular Entities (NME) Drugs Sales by Action Mechanism
2.4.4.1 Global New Molecular Entities (NME) Drugs Sales Market Share by Action Mechanism (2021-2026)
2.4.4.2 Global New Molecular Entities (NME) Drugs Revenue and Market Share by Action Mechanism (2021-2026)
2.4.4.3 Global New Molecular Entities (NME) Drugs Sale Price by Action Mechanism (2021-2026)
2.5 New Molecular Entities (NME) Drugs Segment by Application
2.5.1 Cancer Diseases
2.5.2 Immune Diseases
2.5.3 Cardiovascular Diseases
2.5.4 Others
2.5.5 New Molecular Entities (NME) Drugs Sales by Application
2.5.5.1 Global New Molecular Entities (NME) Drugs Sale Market Share by Application (2021-2026)
2.5.5.2 Global New Molecular Entities (NME) Drugs Revenue and Market Share by Application (2021-2026)
2.5.5.3 Global New Molecular Entities (NME) Drugs Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global New Molecular Entities (NME) Drugs Breakdown Data by Company
3.1.1 Global New Molecular Entities (NME) Drugs Annual Sales by Company (2021-2026)
3.1.2 Global New Molecular Entities (NME) Drugs Sales Market Share by Company (2021-2026)
3.2 Global New Molecular Entities (NME) Drugs Annual Revenue by Company (2021-2026)
3.2.1 Global New Molecular Entities (NME) Drugs Revenue by Company (2021-2026)
3.2.2 Global New Molecular Entities (NME) Drugs Revenue Market Share by Company (2021-2026)
3.3 Global New Molecular Entities (NME) Drugs Sale Price by Company
3.4 Key Manufacturers New Molecular Entities (NME) Drugs Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers New Molecular Entities (NME) Drugs Product Location Distribution
3.4.2 Players New Molecular Entities (NME) Drugs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR NEW MOLECULAR ENTITIES (NME) DRUGS BY GEOGRAPHIC REGION
4.1 World Historic New Molecular Entities (NME) Drugs Market Size by Geographic Region (2021-2026)
4.1.1 Global New Molecular Entities (NME) Drugs Annual Sales by Geographic Region (2021-2026)
4.1.2 Global New Molecular Entities (NME) Drugs Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic New Molecular Entities (NME) Drugs Market Size by Country/Region (2021-2026)
4.2.1 Global New Molecular Entities (NME) Drugs Annual Sales by Country/Region (2021-2026)
4.2.2 Global New Molecular Entities (NME) Drugs Annual Revenue by Country/Region (2021-2026)
4.3 Americas New Molecular Entities (NME) Drugs Sales Growth
4.4 APAC New Molecular Entities (NME) Drugs Sales Growth
4.5 Europe New Molecular Entities (NME) Drugs Sales Growth
4.6 Middle East & Africa New Molecular Entities (NME) Drugs Sales Growth
5 AMERICAS
5.1 Americas New Molecular Entities (NME) Drugs Sales by Country
5.1.1 Americas New Molecular Entities (NME) Drugs Sales by Country (2021-2026)
5.1.2 Americas New Molecular Entities (NME) Drugs Revenue by Country (2021-2026)
5.2 Americas New Molecular Entities (NME) Drugs Sales by Type (2021-2026)
5.3 Americas New Molecular Entities (NME) Drugs Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC New Molecular Entities (NME) Drugs Sales by Region
6.1.1 APAC New Molecular Entities (NME) Drugs Sales by Region (2021-2026)
6.1.2 APAC New Molecular Entities (NME) Drugs Revenue by Region (2021-2026)
6.2 APAC New Molecular Entities (NME) Drugs Sales by Type (2021-2026)
6.3 APAC New Molecular Entities (NME) Drugs Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe New Molecular Entities (NME) Drugs by Country
7.1.1 Europe New Molecular Entities (NME) Drugs Sales by Country (2021-2026)
7.1.2 Europe New Molecular Entities (NME) Drugs Revenue by Country (2021-2026)
7.2 Europe New Molecular Entities (NME) Drugs Sales by Type (2021-2026)
7.3 Europe New Molecular Entities (NME) Drugs Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa New Molecular Entities (NME) Drugs by Country
8.1.1 Middle East & Africa New Molecular Entities (NME) Drugs Sales by Country (2021-2026)
8.1.2 Middle East & Africa New Molecular Entities (NME) Drugs Revenue by Country (2021-2026)
8.2 Middle East & Africa New Molecular Entities (NME) Drugs Sales by Type (2021-2026)
8.3 Middle East & Africa New Molecular Entities (NME) Drugs Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of New Molecular Entities (NME) Drugs
10.3 Manufacturing Process Analysis of New Molecular Entities (NME) Drugs
10.4 Industry Chain Structure of New Molecular Entities (NME) Drugs
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 New Molecular Entities (NME) Drugs Distributors
11.3 New Molecular Entities (NME) Drugs Customer
12 WORLD FORECAST REVIEW FOR NEW MOLECULAR ENTITIES (NME) DRUGS BY GEOGRAPHIC REGION
12.1 Global New Molecular Entities (NME) Drugs Market Size Forecast by Region
12.1.1 Global New Molecular Entities (NME) Drugs Forecast by Region (2027-2032)
12.1.2 Global New Molecular Entities (NME) Drugs Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global New Molecular Entities (NME) Drugs Forecast by Type (2027-2032)
12.7 Global New Molecular Entities (NME) Drugs Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Roche
13.1.1 Roche Company Information
13.1.2 Roche New Molecular Entities (NME) Drugs Product Portfolios and Specifications
13.1.3 Roche New Molecular Entities (NME) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Roche Main Business Overview
13.1.5 Roche Latest Developments
13.2 Novartis
13.2.1 Novartis Company Information
13.2.2 Novartis New Molecular Entities (NME) Drugs Product Portfolios and Specifications
13.2.3 Novartis New Molecular Entities (NME) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Novartis Main Business Overview
13.2.5 Novartis Latest Developments
13.3 Merck
13.3.1 Merck Company Information
13.3.2 Merck New Molecular Entities (NME) Drugs Product Portfolios and Specifications
13.3.3 Merck New Molecular Entities (NME) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Merck Main Business Overview
13.3.5 Merck Latest Developments
13.4 Pfizer
13.4.1 Pfizer Company Information
13.4.2 Pfizer New Molecular Entities (NME) Drugs Product Portfolios and Specifications
13.4.3 Pfizer New Molecular Entities (NME) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Pfizer Main Business Overview
13.4.5 Pfizer Latest Developments
13.5 AstraZeneca
13.5.1 AstraZeneca Company Information
13.5.2 AstraZeneca New Molecular Entities (NME) Drugs Product Portfolios and Specifications
13.5.3 AstraZeneca New Molecular Entities (NME) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 AstraZeneca Main Business Overview
13.5.5 AstraZeneca Latest Developments
13.6 Johnson & Johnson
13.6.1 Johnson & Johnson Company Information
13.6.2 Johnson & Johnson New Molecular Entities (NME) Drugs Product Portfolios and Specifications
13.6.3 Johnson & Johnson New Molecular Entities (NME) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Johnson & Johnson Main Business Overview
13.6.5 Johnson & Johnson Latest Developments
13.7 Bristol Myers Squibb
13.7.1 Bristol Myers Squibb Company Information
13.7.2 Bristol Myers Squibb New Molecular Entities (NME) Drugs Product Portfolios and Specifications
13.7.3 Bristol Myers Squibb New Molecular Entities (NME) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Bristol Myers Squibb Main Business Overview
13.7.5 Bristol Myers Squibb Latest Developments
13.8 Bayer
13.8.1 Bayer Company Information
13.8.2 Bayer New Molecular Entities (NME) Drugs Product Portfolios and Specifications
13.8.3 Bayer New Molecular Entities (NME) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Bayer Main Business Overview
13.8.5 Bayer Latest Developments
13.9 GSK
13.9.1 GSK Company Information
13.9.2 GSK New Molecular Entities (NME) Drugs Product Portfolios and Specifications
13.9.3 GSK New Molecular Entities (NME) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 GSK Main Business Overview
13.9.5 GSK Latest Developments
13.10 Daiichi Sankyo
13.10.1 Daiichi Sankyo Company Information
13.10.2 Daiichi Sankyo New Molecular Entities (NME) Drugs Product Portfolios and Specifications
13.10.3 Daiichi Sankyo New Molecular Entities (NME) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 Daiichi Sankyo Main Business Overview
13.10.5 Daiichi Sankyo Latest Developments
13.11 Amgen
13.11.1 Amgen Company Information
13.11.2 Amgen New Molecular Entities (NME) Drugs Product Portfolios and Specifications
13.11.3 Amgen New Molecular Entities (NME) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 Amgen Main Business Overview
13.11.5 Amgen Latest Developments
13.12 Eli Lilly and Company
13.12.1 Eli Lilly and Company Company Information
13.12.2 Eli Lilly and Company New Molecular Entities (NME) Drugs Product Portfolios and Specifications
13.12.3 Eli Lilly and Company New Molecular Entities (NME) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.12.4 Eli Lilly and Company Main Business Overview
13.12.5 Eli Lilly and Company Latest Developments
13.13 AbbVie
13.13.1 AbbVie Company Information
13.13.2 AbbVie New Molecular Entities (NME) Drugs Product Portfolios and Specifications
13.13.3 AbbVie New Molecular Entities (NME) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.13.4 AbbVie Main Business Overview
13.13.5 AbbVie Latest Developments
13.14 Sanofi
13.14.1 Sanofi Company Information
13.14.2 Sanofi New Molecular Entities (NME) Drugs Product Portfolios and Specifications
13.14.3 Sanofi New Molecular Entities (NME) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.14.4 Sanofi Main Business Overview
13.14.5 Sanofi Latest Developments
13.15 Takeda
13.15.1 Takeda Company Information
13.15.2 Takeda New Molecular Entities (NME) Drugs Product Portfolios and Specifications
13.15.3 Takeda New Molecular Entities (NME) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.15.4 Takeda Main Business Overview
13.15.5 Takeda Latest Developments
13.16 Boehringer Ingelheim
13.16.1 Boehringer Ingelheim Company Information
13.16.2 Boehringer Ingelheim New Molecular Entities (NME) Drugs Product Portfolios and Specifications
13.16.3 Boehringer Ingelheim New Molecular Entities (NME) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.16.4 Boehringer Ingelheim Main Business Overview
13.16.5 Boehringer Ingelheim Latest Developments
13.17 Beigene, Ltd.
13.17.1 Beigene, Ltd. Company Information
13.17.2 Beigene, Ltd. New Molecular Entities (NME) Drugs Product Portfolios and Specifications
13.17.3 Beigene, Ltd. New Molecular Entities (NME) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.17.4 Beigene, Ltd. Main Business Overview
13.17.5 Beigene, Ltd. Latest Developments
13.18 Jiangsu Hengrui Medicine
13.18.1 Jiangsu Hengrui Medicine Company Information
13.18.2 Jiangsu Hengrui Medicine New Molecular Entities (NME) Drugs Product Portfolios and Specifications
13.18.3 Jiangsu Hengrui Medicine New Molecular Entities (NME) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.18.4 Jiangsu Hengrui Medicine Main Business Overview
13.18.5 Jiangsu Hengrui Medicine Latest Developments
13.19 INNOVENT BIOLOGICS(SUZHOU)
13.19.1 INNOVENT BIOLOGICS(SUZHOU) Company Information
13.19.2 INNOVENT BIOLOGICS(SUZHOU) New Molecular Entities (NME) Drugs Product Portfolios and Specifications
13.19.3 INNOVENT BIOLOGICS(SUZHOU) New Molecular Entities (NME) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.19.4 INNOVENT BIOLOGICS(SUZHOU) Main Business Overview
13.19.5 INNOVENT BIOLOGICS(SUZHOU) Latest Developments
13.20 Betta Pharmaceuticals
13.20.1 Betta Pharmaceuticals Company Information
13.20.2 Betta Pharmaceuticals New Molecular Entities (NME) Drugs Product Portfolios and Specifications
13.20.3 Betta Pharmaceuticals New Molecular Entities (NME) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.20.4 Betta Pharmaceuticals Main Business Overview
13.20.5 Betta Pharmaceuticals Latest Developments
13.21 Remegen Co.,Ltd.
13.21.1 Remegen Co.,Ltd. Company Information
13.21.2 Remegen Co.,Ltd. New Molecular Entities (NME) Drugs Product Portfolios and Specifications
13.21.3 Remegen Co.,Ltd. New Molecular Entities (NME) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.21.4 Remegen Co.,Ltd. Main Business Overview
13.21.5 Remegen Co.,Ltd. Latest Developments
13.22 Shanghai Allist Pharmaceuticals
13.22.1 Shanghai Allist Pharmaceuticals Company Information
13.22.2 Shanghai Allist Pharmaceuticals New Molecular Entities (NME) Drugs Product Portfolios and Specifications
13.22.3 Shanghai Allist Pharmaceuticals New Molecular Entities (NME) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.22.4 Shanghai Allist Pharmaceuticals Main Business Overview
13.22.5 Shanghai Allist Pharmaceuticals Latest Developments
13.23 Innocare
13.23.1 Innocare Company Information
13.23.2 Innocare New Molecular Entities (NME) Drugs Product Portfolios and Specifications
13.23.3 Innocare New Molecular Entities (NME) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.23.4 Innocare Main Business Overview
13.23.5 Innocare Latest Developments
13.24 Huiyu Pharmaceuticals
13.24.1 Huiyu Pharmaceuticals Company Information
13.24.2 Huiyu Pharmaceuticals New Molecular Entities (NME) Drugs Product Portfolios and Specifications
13.24.3 Huiyu Pharmaceuticals New Molecular Entities (NME) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.24.4 Huiyu Pharmaceuticals Main Business Overview
13.24.5 Huiyu Pharmaceuticals Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. New Molecular Entities (NME) Drugs Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. New Molecular Entities (NME) Drugs Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Small Molecules
Table 4. Major Players of Monoclonal Antibodies
Table 5. Major Players of ADCs
Table 6. Major Players of Others
Table 7. Global New Molecular Entities (NME) Drugs Sales by Type (2021-2026) & (M Units)
Table 8. Global New Molecular Entities (NME) Drugs Sales Market Share by Type (2021-2026)
Table 9. Global New Molecular Entities (NME) Drugs Revenue by Type (2021-2026) & ($ million)
Table 10. Global New Molecular Entities (NME) Drugs Revenue Market Share by Type (2021-2026)
Table 11. Global New Molecular Entities (NME) Drugs Sale Price by Type (2021-2026) & (US$/Unit)
Table 12. Major Players of Oral Drugs
Table 13. Major Players of Injectable Drugs
Table 14. Major Players of Others
Table 15. Global New Molecular Entities (NME) Drugs Sales by Administration Route (2021-2026) & (M Units)
Table 16. Global New Molecular Entities (NME) Drugs Sales Market Share by Administration Route (2021-2026)
Table 17. Global New Molecular Entities (NME) Drugs Revenue by Administration Route (2021-2026) & ($ million)
Table 18. Global New Molecular Entities (NME) Drugs Revenue Market Share by Administration Route (2021-2026)
Table 19. Global New Molecular Entities (NME) Drugs Sale Price by Administration Route (2021-2026) & (US$/Unit)
Table 20. Major Players of Receptor Agonists
Table 21. Major Players of Enzyme Inhibitors
Table 22. Major Players of Others
Table 23. Global New Molecular Entities (NME) Drugs Sales by Action Mechanism (2021-2026) & (M Units)
Table 24. Global New Molecular Entities (NME) Drugs Sales Market Share by Action Mechanism (2021-2026)
Table 25. Global New Molecular Entities (NME) Drugs Revenue by Action Mechanism (2021-2026) & ($ million)
Table 26. Global New Molecular Entities (NME) Drugs Revenue Market Share by Action Mechanism (2021-2026)
Table 27. Global New Molecular Entities (NME) Drugs Sale Price by Action Mechanism (2021-2026) & (US$/Unit)
Table 28. Global New Molecular Entities (NME) Drugs Sale by Application (2021-2026) & (M Units)
Table 29. Global New Molecular Entities (NME) Drugs Sale Market Share by Application (2021-2026)
Table 30. Global New Molecular Entities (NME) Drugs Revenue by Application (2021-2026) & ($ million)
Table 31. Global New Molecular Entities (NME) Drugs Revenue Market Share by Application (2021-2026)
Table 32. Global New Molecular Entities (NME) Drugs Sale Price by Application (2021-2026) & (US$/Unit)
Table 33. Global New Molecular Entities (NME) Drugs Sales by Company (2021-2026) & (M Units)
Table 34. Global New Molecular Entities (NME) Drugs Sales Market Share by Company (2021-2026)
Table 35. Global New Molecular Entities (NME) Drugs Revenue by Company (2021-2026) & ($ millions)
Table 36. Global New Molecular Entities (NME) Drugs Revenue Market Share by Company (2021-2026)
Table 37. Global New Molecular Entities (NME) Drugs Sale Price by Company (2021-2026) & (US$/Unit)
Table 38. Key Manufacturers New Molecular Entities (NME) Drugs Producing Area Distribution and Sales Area
Table 39. Players New Molecular Entities (NME) Drugs Products Offered
Table 40. New Molecular Entities (NME) Drugs Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 41. New Products and Potential Entrants
Table 42. Market M&A Activity & Strategy
Table 43. Global New Molecular Entities (NME) Drugs Sales by Geographic Region (2021-2026) & (M Units)
Table 44. Global New Molecular Entities (NME) Drugs Sales Market Share Geographic Region (2021-2026)
Table 45. Global New Molecular Entities (NME) Drugs Revenue by Geographic Region (2021-2026) & ($ millions)
Table 46. Global New Molecular Entities (NME) Drugs Revenue Market Share by Geographic Region (2021-2026)
Table 47. Global New Molecular Entities (NME) Drugs Sales by Country/Region (2021-2026) & (M Units)
Table 48. Global New Molecular Entities (NME) Drugs Sales Market Share by Country/Region (2021-2026)
Table 49. Global New Molecular Entities (NME) Drugs Revenue by Country/Region (2021-2026) & ($ millions)
Table 50. Global New Molecular Entities (NME) Drugs Revenue Market Share by Country/Region (2021-2026)
Table 51. Americas New Molecular Entities (NME) Drugs Sales by Country (2021-2026) & (M Units)
Table 52. Americas New Molecular Entities (NME) Drugs Sales Market Share by Country (2021-2026)
Table 53. Americas New Molecular Entities (NME) Drugs Revenue by Country (2021-2026) & ($ millions)
Table 54. Americas New Molecular Entities (NME) Drugs Sales by Type (2021-2026) & (M Units)
Table 55. Americas New Molecular Entities (NME) Drugs Sales by Application (2021-2026) & (M Units)
Table 56. APAC New Molecular Entities (NME) Drugs Sales by Region (2021-2026) & (M Units)
Table 57. APAC New Molecular Entities (NME) Drugs Sales Market Share by Region (2021-2026)
Table 58. APAC New Molecular Entities (NME) Drugs Revenue by Region (2021-2026) & ($ millions)
Table 59. APAC New Molecular Entities (NME) Drugs Sales by Type (2021-2026) & (M Units)
Table 60. APAC New Molecular Entities (NME) Drugs Sales by Application (2021-2026) & (M Units)
Table 61. Europe New Molecular Entities (NME) Drugs Sales by Country (2021-2026) & (M Units)
Table 62. Europe New Molecular Entities (NME) Drugs Revenue by Country (2021-2026) & ($ millions)
Table 63. Europe New Molecular Entities (NME) Drugs Sales by Type (2021-2026) & (M Units)
Table 64. Europe New Molecular Entities (NME) Drugs Sales by Application (2021-2026) & (M Units)
Table 65. Middle East & Africa New Molecular Entities (NME) Drugs Sales by Country (2021-2026) & (M Units)
Table 66. Middle East & Africa New Molecular Entities (NME) Drugs Revenue Market Share by Country (2021-2026)
Table 67. Middle East & Africa New Molecular Entities (NME) Drugs Sales by Type (2021-2026) & (M Units)
Table 68. Middle East & Africa New Molecular Entities (NME) Drugs Sales by Application (2021-2026) & (M Units)
Table 69. Key Market Drivers & Growth Opportunities of New Molecular Entities (NME) Drugs
Table 70. Key Market Challenges & Risks of New Molecular Entities (NME) Drugs
Table 71. Key Industry Trends of New Molecular Entities (NME) Drugs
Table 72. New Molecular Entities (NME) Drugs Raw Material
Table 73. Key Suppliers of Raw Materials
Table 74. New Molecular Entities (NME) Drugs Distributors List
Table 75. New Molecular Entities (NME) Drugs Customer List
Table 76. Global New Molecular Entities (NME) Drugs Sales Forecast by Region (2027-2032) & (M Units)
Table 77. Global New Molecular Entities (NME) Drugs Revenue Forecast by Region (2027-2032) & ($ millions)
Table 78. Americas New Molecular Entities (NME) Drugs Sales Forecast by Country (2027-2032) & (M Units)
Table 79. Americas New Molecular Entities (NME) Drugs Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 80. APAC New Molecular Entities (NME) Drugs Sales Forecast by Region (2027-2032) & (M Units)
Table 81. APAC New Molecular Entities (NME) Drugs Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 82. Europe New Molecular Entities (NME) Drugs Sales Forecast by Country (2027-2032) & (M Units)
Table 83. Europe New Molecular Entities (NME) Drugs Revenue Forecast by Country (2027-2032) & ($ millions)
Table 84. Middle East & Africa New Molecular Entities (NME) Drugs Sales Forecast by Country (2027-2032) & (M Units)
Table 85. Middle East & Africa New Molecular Entities (NME) Drugs Revenue Forecast by Country (2027-2032) & ($ millions)
Table 86. Global New Molecular Entities (NME) Drugs Sales Forecast by Type (2027-2032) & (M Units)
Table 87. Global New Molecular Entities (NME) Drugs Revenue Forecast by Type (2027-2032) & ($ millions)
Table 88. Global New Molecular Entities (NME) Drugs Sales Forecast by Application (2027-2032) & (M Units)
Table 89. Global New Molecular Entities (NME) Drugs Revenue Forecast by Application (2027-2032) & ($ millions)
Table 90. Roche Basic Information, New Molecular Entities (NME) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 91. Roche New Molecular Entities (NME) Drugs Product Portfolios and Specifications
Table 92. Roche New Molecular Entities (NME) Drugs Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 93. Roche Main Business
Table 94. Roche Latest Developments
Table 95. Novartis Basic Information, New Molecular Entities (NME) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 96. Novartis New Molecular Entities (NME) Drugs Product Portfolios and Specifications
Table 97. Novartis New Molecular Entities (NME) Drugs Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 98. Novartis Main Business
Table 99. Novartis Latest Developments
Table 100. Merck Basic Information, New Molecular Entities (NME) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 101. Merck New Molecular Entities (NME) Drugs Product Portfolios and Specifications
Table 102. Merck New Molecular Entities (NME) Drugs Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 103. Merck Main Business
Table 104. Merck Latest Developments
Table 105. Pfizer Basic Information, New Molecular Entities (NME) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 106. Pfizer New Molecular Entities (NME) Drugs Product Portfolios and Specifications
Table 107. Pfizer New Molecular Entities (NME) Drugs Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 108. Pfizer Main Business
Table 109. Pfizer Latest Developments
Table 110. AstraZeneca Basic Information, New Molecular Entities (NME) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 111. AstraZeneca New Molecular Entities (NME) Drugs Product Portfolios and Specifications
Table 112. AstraZeneca New Molecular Entities (NME) Drugs Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 113. AstraZeneca Main Business
Table 114. AstraZeneca Latest Developments
Table 115. Johnson & Johnson Basic Information, New Molecular Entities (NME) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 116. Johnson & Johnson New Molecular Entities (NME) Drugs Product Portfolios and Specifications
Table 117. Johnson & Johnson New Molecular Entities (NME) Drugs Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 118. Johnson & Johnson Main Business
Table 119. Johnson & Johnson Latest Developments
Table 120. Bristol Myers Squibb Basic Information, New Molecular Entities (NME) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 121. Bristol Myers Squibb New Molecular Entities (NME) Drugs Product Portfolios and Specifications
Table 122. Bristol Myers Squibb New Molecular Entities (NME) Drugs Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 123. Bristol Myers Squibb Main Business
Table 124. Bristol Myers Squibb Latest Developments
Table 125. Bayer Basic Information, New Molecular Entities (NME) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 126. Bayer New Molecular Entities (NME) Drugs Product Portfolios and Specifications
Table 127. Bayer New Molecular Entities (NME) Drugs Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 128. Bayer Main Business
Table 129. Bayer Latest Developments
Table 130. GSK Basic Information, New Molecular Entities (NME) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 131. GSK New Molecular Entities (NME) Drugs Product Portfolios and Specifications
Table 132. GSK New Molecular Entities (NME) Drugs Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 133. GSK Main Business
Table 134. GSK Latest Developments
Table 135. Daiichi Sankyo Basic Information, New Molecular Entities (NME) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 136. Daiichi Sankyo New Molecular Entities (NME) Drugs Product Portfolios and Specifications
Table 137. Daiichi Sankyo New Molecular Entities (NME) Drugs Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 138. Daiichi Sankyo Main Business
Table 139. Daiichi Sankyo Latest Developments
Table 140. Amgen Basic Information, New Molecular Entities (NME) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 141. Amgen New Molecular Entities (NME) Drugs Product Portfolios and Specifications
Table 142. Amgen New Molecular Entities (NME) Drugs Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 143. Amgen Main Business
Table 144. Amgen Latest Developments
Table 145. Eli Lilly and Company Basic Information, New Molecular Entities (NME) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 146. Eli Lilly and Company New Molecular Entities (NME) Drugs Product Portfolios and Specifications
Table 147. Eli Lilly and Company New Molecular Entities (NME) Drugs Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 148. Eli Lilly and Company Main Business
Table 149. Eli Lilly and Company Latest Developments
Table 150. AbbVie Basic Information, New Molecular Entities (NME) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 151. AbbVie New Molecular Entities (NME) Drugs Product Portfolios and Specifications
Table 152. AbbVie New Molecular Entities (NME) Drugs Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 153. AbbVie Main Business
Table 154. AbbVie Latest Developments
Table 155. Sanofi Basic Information, New Molecular Entities (NME) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 156. Sanofi New Molecular Entities (NME) Drugs Product Portfolios and Specifications
Table 157. Sanofi New Molecular Entities (NME) Drugs Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 158. Sanofi Main Business
Table 159. Sanofi Latest Developments
Table 160. Takeda Basic Information, New Molecular Entities (NME) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 161. Takeda New Molecular Entities (NME) Drugs Product Portfolios and Specifications
Table 162. Takeda New Molecular Entities (NME) Drugs Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 163. Takeda Main Business
Table 164. Takeda Latest Developments
Table 165. Boehringer Ingelheim Basic Information, New Molecular Entities (NME) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 166. Boehringer Ingelheim New Molecular Entities (NME) Drugs Product Portfolios and Specifications
Table 167. Boehringer Ingelheim New Molecular Entities (NME) Drugs Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 168. Boehringer Ingelheim Main Business
Table 169. Boehringer Ingelheim Latest Developments
Table 170. Beigene, Ltd. Basic Information, New Molecular Entities (NME) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 171. Beigene, Ltd. New Molecular Entities (NME) Drugs Product Portfolios and Specifications
Table 172. Beigene, Ltd. New Molecular Entities (NME) Drugs Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 173. Beigene, Ltd. Main Business
Table 174. Beigene, Ltd. Latest Developments
Table 175. Jiangsu Hengrui Medicine Basic Information, New Molecular Entities (NME) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 176. Jiangsu Hengrui Medicine New Molecular Entities (NME) Drugs Product Portfolios and Specifications
Table 177. Jiangsu Hengrui Medicine New Molecular Entities (NME) Drugs Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 178. Jiangsu Hengrui Medicine Main Business
Table 179. Jiangsu Hengrui Medicine Latest Developments
Table 180. INNOVENT BIOLOGICS(SUZHOU) Basic Information, New Molecular Entities (NME) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 181. INNOVENT BIOLOGICS(SUZHOU) New Molecular Entities (NME) Drugs Product Portfolios and Specifications
Table 182. INNOVENT BIOLOGICS(SUZHOU) New Molecular Entities (NME) Drugs Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 183. INNOVENT BIOLOGICS(SUZHOU) Main Business
Table 184. INNOVENT BIOLOGICS(SUZHOU) Latest Developments
Table 185. Betta Pharmaceuticals Basic Information, New Molecular Entities (NME) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 186. Betta Pharmaceuticals New Molecular Entities (NME) Drugs Product Portfolios and Specifications
Table 187. Betta Pharmaceuticals New Molecular Entities (NME) Drugs Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 188. Betta Pharmaceuticals Main Business
Table 189. Betta Pharmaceuticals Latest Developments
Table 190. Remegen Co.,Ltd. Basic Information, New Molecular Entities (NME) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 191. Remegen Co.,Ltd. New Molecular Entities (NME) Drugs Product Portfolios and Specifications
Table 192. Remegen Co.,Ltd. New Molecular Entities (NME) Drugs Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 193. Remegen Co.,Ltd. Main Business
Table 194. Remegen Co.,Ltd. Latest Developments
Table 195. Shanghai Allist Pharmaceuticals Basic Information, New Molecular Entities (NME) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 196. Shanghai Allist Pharmaceuticals New Molecular Entities (NME) Drugs Product Portfolios and Specifications
Table 197. Shanghai Allist Pharmaceuticals New Molecular Entities (NME) Drugs Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 198. Shanghai Allist Pharmaceuticals Main Business
Table 199. Shanghai Allist Pharmaceuticals Latest Developments
Table 200. Innocare Basic Information, New Molecular Entities (NME) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 201. Innocare New Molecular Entities (NME) Drugs Product Portfolios and Specifications
Table 202. Innocare New Molecular Entities (NME) Drugs Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 203. Innocare Main Business
Table 204. Innocare Latest Developments
Table 205. Huiyu Pharmaceuticals Basic Information, New Molecular Entities (NME) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 206. Huiyu Pharmaceuticals New Molecular Entities (NME) Drugs Product Portfolios and Specifications
Table 207. Huiyu Pharmaceuticals New Molecular Entities (NME) Drugs Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 208. Huiyu Pharmaceuticals Main Business
Table 209. Huiyu Pharmaceuticals Latest Developments
Table 1. New Molecular Entities (NME) Drugs Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. New Molecular Entities (NME) Drugs Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Small Molecules
Table 4. Major Players of Monoclonal Antibodies
Table 5. Major Players of ADCs
Table 6. Major Players of Others
Table 7. Global New Molecular Entities (NME) Drugs Sales by Type (2021-2026) & (M Units)
Table 8. Global New Molecular Entities (NME) Drugs Sales Market Share by Type (2021-2026)
Table 9. Global New Molecular Entities (NME) Drugs Revenue by Type (2021-2026) & ($ million)
Table 10. Global New Molecular Entities (NME) Drugs Revenue Market Share by Type (2021-2026)
Table 11. Global New Molecular Entities (NME) Drugs Sale Price by Type (2021-2026) & (US$/Unit)
Table 12. Major Players of Oral Drugs
Table 13. Major Players of Injectable Drugs
Table 14. Major Players of Others
Table 15. Global New Molecular Entities (NME) Drugs Sales by Administration Route (2021-2026) & (M Units)
Table 16. Global New Molecular Entities (NME) Drugs Sales Market Share by Administration Route (2021-2026)
Table 17. Global New Molecular Entities (NME) Drugs Revenue by Administration Route (2021-2026) & ($ million)
Table 18. Global New Molecular Entities (NME) Drugs Revenue Market Share by Administration Route (2021-2026)
Table 19. Global New Molecular Entities (NME) Drugs Sale Price by Administration Route (2021-2026) & (US$/Unit)
Table 20. Major Players of Receptor Agonists
Table 21. Major Players of Enzyme Inhibitors
Table 22. Major Players of Others
Table 23. Global New Molecular Entities (NME) Drugs Sales by Action Mechanism (2021-2026) & (M Units)
Table 24. Global New Molecular Entities (NME) Drugs Sales Market Share by Action Mechanism (2021-2026)
Table 25. Global New Molecular Entities (NME) Drugs Revenue by Action Mechanism (2021-2026) & ($ million)
Table 26. Global New Molecular Entities (NME) Drugs Revenue Market Share by Action Mechanism (2021-2026)
Table 27. Global New Molecular Entities (NME) Drugs Sale Price by Action Mechanism (2021-2026) & (US$/Unit)
Table 28. Global New Molecular Entities (NME) Drugs Sale by Application (2021-2026) & (M Units)
Table 29. Global New Molecular Entities (NME) Drugs Sale Market Share by Application (2021-2026)
Table 30. Global New Molecular Entities (NME) Drugs Revenue by Application (2021-2026) & ($ million)
Table 31. Global New Molecular Entities (NME) Drugs Revenue Market Share by Application (2021-2026)
Table 32. Global New Molecular Entities (NME) Drugs Sale Price by Application (2021-2026) & (US$/Unit)
Table 33. Global New Molecular Entities (NME) Drugs Sales by Company (2021-2026) & (M Units)
Table 34. Global New Molecular Entities (NME) Drugs Sales Market Share by Company (2021-2026)
Table 35. Global New Molecular Entities (NME) Drugs Revenue by Company (2021-2026) & ($ millions)
Table 36. Global New Molecular Entities (NME) Drugs Revenue Market Share by Company (2021-2026)
Table 37. Global New Molecular Entities (NME) Drugs Sale Price by Company (2021-2026) & (US$/Unit)
Table 38. Key Manufacturers New Molecular Entities (NME) Drugs Producing Area Distribution and Sales Area
Table 39. Players New Molecular Entities (NME) Drugs Products Offered
Table 40. New Molecular Entities (NME) Drugs Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 41. New Products and Potential Entrants
Table 42. Market M&A Activity & Strategy
Table 43. Global New Molecular Entities (NME) Drugs Sales by Geographic Region (2021-2026) & (M Units)
Table 44. Global New Molecular Entities (NME) Drugs Sales Market Share Geographic Region (2021-2026)
Table 45. Global New Molecular Entities (NME) Drugs Revenue by Geographic Region (2021-2026) & ($ millions)
Table 46. Global New Molecular Entities (NME) Drugs Revenue Market Share by Geographic Region (2021-2026)
Table 47. Global New Molecular Entities (NME) Drugs Sales by Country/Region (2021-2026) & (M Units)
Table 48. Global New Molecular Entities (NME) Drugs Sales Market Share by Country/Region (2021-2026)
Table 49. Global New Molecular Entities (NME) Drugs Revenue by Country/Region (2021-2026) & ($ millions)
Table 50. Global New Molecular Entities (NME) Drugs Revenue Market Share by Country/Region (2021-2026)
Table 51. Americas New Molecular Entities (NME) Drugs Sales by Country (2021-2026) & (M Units)
Table 52. Americas New Molecular Entities (NME) Drugs Sales Market Share by Country (2021-2026)
Table 53. Americas New Molecular Entities (NME) Drugs Revenue by Country (2021-2026) & ($ millions)
Table 54. Americas New Molecular Entities (NME) Drugs Sales by Type (2021-2026) & (M Units)
Table 55. Americas New Molecular Entities (NME) Drugs Sales by Application (2021-2026) & (M Units)
Table 56. APAC New Molecular Entities (NME) Drugs Sales by Region (2021-2026) & (M Units)
Table 57. APAC New Molecular Entities (NME) Drugs Sales Market Share by Region (2021-2026)
Table 58. APAC New Molecular Entities (NME) Drugs Revenue by Region (2021-2026) & ($ millions)
Table 59. APAC New Molecular Entities (NME) Drugs Sales by Type (2021-2026) & (M Units)
Table 60. APAC New Molecular Entities (NME) Drugs Sales by Application (2021-2026) & (M Units)
Table 61. Europe New Molecular Entities (NME) Drugs Sales by Country (2021-2026) & (M Units)
Table 62. Europe New Molecular Entities (NME) Drugs Revenue by Country (2021-2026) & ($ millions)
Table 63. Europe New Molecular Entities (NME) Drugs Sales by Type (2021-2026) & (M Units)
Table 64. Europe New Molecular Entities (NME) Drugs Sales by Application (2021-2026) & (M Units)
Table 65. Middle East & Africa New Molecular Entities (NME) Drugs Sales by Country (2021-2026) & (M Units)
Table 66. Middle East & Africa New Molecular Entities (NME) Drugs Revenue Market Share by Country (2021-2026)
Table 67. Middle East & Africa New Molecular Entities (NME) Drugs Sales by Type (2021-2026) & (M Units)
Table 68. Middle East & Africa New Molecular Entities (NME) Drugs Sales by Application (2021-2026) & (M Units)
Table 69. Key Market Drivers & Growth Opportunities of New Molecular Entities (NME) Drugs
Table 70. Key Market Challenges & Risks of New Molecular Entities (NME) Drugs
Table 71. Key Industry Trends of New Molecular Entities (NME) Drugs
Table 72. New Molecular Entities (NME) Drugs Raw Material
Table 73. Key Suppliers of Raw Materials
Table 74. New Molecular Entities (NME) Drugs Distributors List
Table 75. New Molecular Entities (NME) Drugs Customer List
Table 76. Global New Molecular Entities (NME) Drugs Sales Forecast by Region (2027-2032) & (M Units)
Table 77. Global New Molecular Entities (NME) Drugs Revenue Forecast by Region (2027-2032) & ($ millions)
Table 78. Americas New Molecular Entities (NME) Drugs Sales Forecast by Country (2027-2032) & (M Units)
Table 79. Americas New Molecular Entities (NME) Drugs Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 80. APAC New Molecular Entities (NME) Drugs Sales Forecast by Region (2027-2032) & (M Units)
Table 81. APAC New Molecular Entities (NME) Drugs Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 82. Europe New Molecular Entities (NME) Drugs Sales Forecast by Country (2027-2032) & (M Units)
Table 83. Europe New Molecular Entities (NME) Drugs Revenue Forecast by Country (2027-2032) & ($ millions)
Table 84. Middle East & Africa New Molecular Entities (NME) Drugs Sales Forecast by Country (2027-2032) & (M Units)
Table 85. Middle East & Africa New Molecular Entities (NME) Drugs Revenue Forecast by Country (2027-2032) & ($ millions)
Table 86. Global New Molecular Entities (NME) Drugs Sales Forecast by Type (2027-2032) & (M Units)
Table 87. Global New Molecular Entities (NME) Drugs Revenue Forecast by Type (2027-2032) & ($ millions)
Table 88. Global New Molecular Entities (NME) Drugs Sales Forecast by Application (2027-2032) & (M Units)
Table 89. Global New Molecular Entities (NME) Drugs Revenue Forecast by Application (2027-2032) & ($ millions)
Table 90. Roche Basic Information, New Molecular Entities (NME) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 91. Roche New Molecular Entities (NME) Drugs Product Portfolios and Specifications
Table 92. Roche New Molecular Entities (NME) Drugs Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 93. Roche Main Business
Table 94. Roche Latest Developments
Table 95. Novartis Basic Information, New Molecular Entities (NME) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 96. Novartis New Molecular Entities (NME) Drugs Product Portfolios and Specifications
Table 97. Novartis New Molecular Entities (NME) Drugs Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 98. Novartis Main Business
Table 99. Novartis Latest Developments
Table 100. Merck Basic Information, New Molecular Entities (NME) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 101. Merck New Molecular Entities (NME) Drugs Product Portfolios and Specifications
Table 102. Merck New Molecular Entities (NME) Drugs Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 103. Merck Main Business
Table 104. Merck Latest Developments
Table 105. Pfizer Basic Information, New Molecular Entities (NME) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 106. Pfizer New Molecular Entities (NME) Drugs Product Portfolios and Specifications
Table 107. Pfizer New Molecular Entities (NME) Drugs Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 108. Pfizer Main Business
Table 109. Pfizer Latest Developments
Table 110. AstraZeneca Basic Information, New Molecular Entities (NME) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 111. AstraZeneca New Molecular Entities (NME) Drugs Product Portfolios and Specifications
Table 112. AstraZeneca New Molecular Entities (NME) Drugs Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 113. AstraZeneca Main Business
Table 114. AstraZeneca Latest Developments
Table 115. Johnson & Johnson Basic Information, New Molecular Entities (NME) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 116. Johnson & Johnson New Molecular Entities (NME) Drugs Product Portfolios and Specifications
Table 117. Johnson & Johnson New Molecular Entities (NME) Drugs Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 118. Johnson & Johnson Main Business
Table 119. Johnson & Johnson Latest Developments
Table 120. Bristol Myers Squibb Basic Information, New Molecular Entities (NME) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 121. Bristol Myers Squibb New Molecular Entities (NME) Drugs Product Portfolios and Specifications
Table 122. Bristol Myers Squibb New Molecular Entities (NME) Drugs Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 123. Bristol Myers Squibb Main Business
Table 124. Bristol Myers Squibb Latest Developments
Table 125. Bayer Basic Information, New Molecular Entities (NME) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 126. Bayer New Molecular Entities (NME) Drugs Product Portfolios and Specifications
Table 127. Bayer New Molecular Entities (NME) Drugs Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 128. Bayer Main Business
Table 129. Bayer Latest Developments
Table 130. GSK Basic Information, New Molecular Entities (NME) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 131. GSK New Molecular Entities (NME) Drugs Product Portfolios and Specifications
Table 132. GSK New Molecular Entities (NME) Drugs Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 133. GSK Main Business
Table 134. GSK Latest Developments
Table 135. Daiichi Sankyo Basic Information, New Molecular Entities (NME) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 136. Daiichi Sankyo New Molecular Entities (NME) Drugs Product Portfolios and Specifications
Table 137. Daiichi Sankyo New Molecular Entities (NME) Drugs Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 138. Daiichi Sankyo Main Business
Table 139. Daiichi Sankyo Latest Developments
Table 140. Amgen Basic Information, New Molecular Entities (NME) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 141. Amgen New Molecular Entities (NME) Drugs Product Portfolios and Specifications
Table 142. Amgen New Molecular Entities (NME) Drugs Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 143. Amgen Main Business
Table 144. Amgen Latest Developments
Table 145. Eli Lilly and Company Basic Information, New Molecular Entities (NME) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 146. Eli Lilly and Company New Molecular Entities (NME) Drugs Product Portfolios and Specifications
Table 147. Eli Lilly and Company New Molecular Entities (NME) Drugs Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 148. Eli Lilly and Company Main Business
Table 149. Eli Lilly and Company Latest Developments
Table 150. AbbVie Basic Information, New Molecular Entities (NME) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 151. AbbVie New Molecular Entities (NME) Drugs Product Portfolios and Specifications
Table 152. AbbVie New Molecular Entities (NME) Drugs Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 153. AbbVie Main Business
Table 154. AbbVie Latest Developments
Table 155. Sanofi Basic Information, New Molecular Entities (NME) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 156. Sanofi New Molecular Entities (NME) Drugs Product Portfolios and Specifications
Table 157. Sanofi New Molecular Entities (NME) Drugs Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 158. Sanofi Main Business
Table 159. Sanofi Latest Developments
Table 160. Takeda Basic Information, New Molecular Entities (NME) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 161. Takeda New Molecular Entities (NME) Drugs Product Portfolios and Specifications
Table 162. Takeda New Molecular Entities (NME) Drugs Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 163. Takeda Main Business
Table 164. Takeda Latest Developments
Table 165. Boehringer Ingelheim Basic Information, New Molecular Entities (NME) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 166. Boehringer Ingelheim New Molecular Entities (NME) Drugs Product Portfolios and Specifications
Table 167. Boehringer Ingelheim New Molecular Entities (NME) Drugs Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 168. Boehringer Ingelheim Main Business
Table 169. Boehringer Ingelheim Latest Developments
Table 170. Beigene, Ltd. Basic Information, New Molecular Entities (NME) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 171. Beigene, Ltd. New Molecular Entities (NME) Drugs Product Portfolios and Specifications
Table 172. Beigene, Ltd. New Molecular Entities (NME) Drugs Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 173. Beigene, Ltd. Main Business
Table 174. Beigene, Ltd. Latest Developments
Table 175. Jiangsu Hengrui Medicine Basic Information, New Molecular Entities (NME) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 176. Jiangsu Hengrui Medicine New Molecular Entities (NME) Drugs Product Portfolios and Specifications
Table 177. Jiangsu Hengrui Medicine New Molecular Entities (NME) Drugs Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 178. Jiangsu Hengrui Medicine Main Business
Table 179. Jiangsu Hengrui Medicine Latest Developments
Table 180. INNOVENT BIOLOGICS(SUZHOU) Basic Information, New Molecular Entities (NME) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 181. INNOVENT BIOLOGICS(SUZHOU) New Molecular Entities (NME) Drugs Product Portfolios and Specifications
Table 182. INNOVENT BIOLOGICS(SUZHOU) New Molecular Entities (NME) Drugs Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 183. INNOVENT BIOLOGICS(SUZHOU) Main Business
Table 184. INNOVENT BIOLOGICS(SUZHOU) Latest Developments
Table 185. Betta Pharmaceuticals Basic Information, New Molecular Entities (NME) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 186. Betta Pharmaceuticals New Molecular Entities (NME) Drugs Product Portfolios and Specifications
Table 187. Betta Pharmaceuticals New Molecular Entities (NME) Drugs Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 188. Betta Pharmaceuticals Main Business
Table 189. Betta Pharmaceuticals Latest Developments
Table 190. Remegen Co.,Ltd. Basic Information, New Molecular Entities (NME) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 191. Remegen Co.,Ltd. New Molecular Entities (NME) Drugs Product Portfolios and Specifications
Table 192. Remegen Co.,Ltd. New Molecular Entities (NME) Drugs Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 193. Remegen Co.,Ltd. Main Business
Table 194. Remegen Co.,Ltd. Latest Developments
Table 195. Shanghai Allist Pharmaceuticals Basic Information, New Molecular Entities (NME) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 196. Shanghai Allist Pharmaceuticals New Molecular Entities (NME) Drugs Product Portfolios and Specifications
Table 197. Shanghai Allist Pharmaceuticals New Molecular Entities (NME) Drugs Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 198. Shanghai Allist Pharmaceuticals Main Business
Table 199. Shanghai Allist Pharmaceuticals Latest Developments
Table 200. Innocare Basic Information, New Molecular Entities (NME) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 201. Innocare New Molecular Entities (NME) Drugs Product Portfolios and Specifications
Table 202. Innocare New Molecular Entities (NME) Drugs Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 203. Innocare Main Business
Table 204. Innocare Latest Developments
Table 205. Huiyu Pharmaceuticals Basic Information, New Molecular Entities (NME) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 206. Huiyu Pharmaceuticals New Molecular Entities (NME) Drugs Product Portfolios and Specifications
Table 207. Huiyu Pharmaceuticals New Molecular Entities (NME) Drugs Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 208. Huiyu Pharmaceuticals Main Business
Table 209. Huiyu Pharmaceuticals Latest Developments
LIST OF FIGURES
Figure 1. Picture of New Molecular Entities (NME) Drugs
Figure 2. New Molecular Entities (NME) Drugs Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global New Molecular Entities (NME) Drugs Sales Growth Rate 2021-2032 (M Units)
Figure 7. Global New Molecular Entities (NME) Drugs Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. New Molecular Entities (NME) Drugs Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. New Molecular Entities (NME) Drugs Sales Market Share by Country/Region (2025)
Figure 10. New Molecular Entities (NME) Drugs Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Small Molecules
Figure 12. Product Picture of Monoclonal Antibodies
Figure 13. Product Picture of ADCs
Figure 14. Product Picture of Others
Figure 15. Global New Molecular Entities (NME) Drugs Sales Market Share by Type in 2026
Figure 16. Global New Molecular Entities (NME) Drugs Revenue Market Share by Type (2021-2026)
Figure 17. Product Picture of Oral Drugs
Figure 18. Product Picture of Injectable Drugs
Figure 19. Product Picture of Others
Figure 20. Global New Molecular Entities (NME) Drugs Sales Market Share by Administration Route in 2026
Figure 21. Global New Molecular Entities (NME) Drugs Revenue Market Share by Administration Route (2021-2026)
Figure 22. Product Picture of Receptor Agonists
Figure 23. Product Picture of Enzyme Inhibitors
Figure 24. Product Picture of Others
Figure 25. Global New Molecular Entities (NME) Drugs Sales Market Share by Action Mechanism in 2026
Figure 26. Global New Molecular Entities (NME) Drugs Revenue Market Share by Action Mechanism (2021-2026)
Figure 27. New Molecular Entities (NME) Drugs Consumed in Cancer Diseases
Figure 28. Global New Molecular Entities (NME) Drugs Market: Cancer Diseases (2021-2026) & (M Units)
Figure 29. New Molecular Entities (NME) Drugs Consumed in Immune Diseases
Figure 30. Global New Molecular Entities (NME) Drugs Market: Immune Diseases (2021-2026) & (M Units)
Figure 31. New Molecular Entities (NME) Drugs Consumed in Cardiovascular Diseases
Figure 32. Global New Molecular Entities (NME) Drugs Market: Cardiovascular Diseases (2021-2026) & (M Units)
Figure 33. New Molecular Entities (NME) Drugs Consumed in Others
Figure 34. Global New Molecular Entities (NME) Drugs Market: Others (2021-2026) & (M Units)
Figure 35. Global New Molecular Entities (NME) Drugs Sale Market Share by Application (2025)
Figure 36. Global New Molecular Entities (NME) Drugs Revenue Market Share by Application in 2026
Figure 37. New Molecular Entities (NME) Drugs Sales by Company in 2026 (M Units)
Figure 38. Global New Molecular Entities (NME) Drugs Sales Market Share by Company in 2026
Figure 39. New Molecular Entities (NME) Drugs Revenue by Company in 2026 ($ millions)
Figure 40. Global New Molecular Entities (NME) Drugs Revenue Market Share by Company in 2026
Figure 41. Global New Molecular Entities (NME) Drugs Sales Market Share by Geographic Region (2021-2026)
Figure 42. Global New Molecular Entities (NME) Drugs Revenue Market Share by Geographic Region in 2026
Figure 43. Americas New Molecular Entities (NME) Drugs Sales 2021-2026 (M Units)
Figure 44. Americas New Molecular Entities (NME) Drugs Revenue 2021-2026 ($ millions)
Figure 45. APAC New Molecular Entities (NME) Drugs Sales 2021-2026 (M Units)
Figure 46. APAC New Molecular Entities (NME) Drugs Revenue 2021-2026 ($ millions)
Figure 47. Europe New Molecular Entities (NME) Drugs Sales 2021-2026 (M Units)
Figure 48. Europe New Molecular Entities (NME) Drugs Revenue 2021-2026 ($ millions)
Figure 49. Middle East & Africa New Molecular Entities (NME) Drugs Sales 2021-2026 (M Units)
Figure 50. Middle East & Africa New Molecular Entities (NME) Drugs Revenue 2021-2026 ($ millions)
Figure 51. Americas New Molecular Entities (NME) Drugs Sales Market Share by Country in 2026
Figure 52. Americas New Molecular Entities (NME) Drugs Revenue Market Share by Country (2021-2026)
Figure 53. Americas New Molecular Entities (NME) Drugs Sales Market Share by Type (2021-2026)
Figure 54. Americas New Molecular Entities (NME) Drugs Sales Market Share by Application (2021-2026)
Figure 55. United States New Molecular Entities (NME) Drugs Revenue Growth 2021-2026 ($ millions)
Figure 56. Canada New Molecular Entities (NME) Drugs Revenue Growth 2021-2026 ($ millions)
Figure 57. Mexico New Molecular Entities (NME) Drugs Revenue Growth 2021-2026 ($ millions)
Figure 58. Brazil New Molecular Entities (NME) Drugs Revenue Growth 2021-2026 ($ millions)
Figure 59. APAC New Molecular Entities (NME) Drugs Sales Market Share by Region in 2026
Figure 60. APAC New Molecular Entities (NME) Drugs Revenue Market Share by Region (2021-2026)
Figure 61. APAC New Molecular Entities (NME) Drugs Sales Market Share by Type (2021-2026)
Figure 62. APAC New Molecular Entities (NME) Drugs Sales Market Share by Application (2021-2026)
Figure 63. China New Molecular Entities (NME) Drugs Revenue Growth 2021-2026 ($ millions)
Figure 64. Japan New Molecular Entities (NME) Drugs Revenue Growth 2021-2026 ($ millions)
Figure 65. South Korea New Molecular Entities (NME) Drugs Revenue Growth 2021-2026 ($ millions)
Figure 66. Southeast Asia New Molecular Entities (NME) Drugs Revenue Growth 2021-2026 ($ millions)
Figure 67. India New Molecular Entities (NME) Drugs Revenue Growth 2021-2026 ($ millions)
Figure 68. Australia New Molecular Entities (NME) Drugs Revenue Growth 2021-2026 ($ millions)
Figure 69. China Taiwan New Molecular Entities (NME) Drugs Revenue Growth 2021-2026 ($ millions)
Figure 70. Europe New Molecular Entities (NME) Drugs Sales Market Share by Country in 2026
Figure 71. Europe New Molecular Entities (NME) Drugs Revenue Market Share by Country (2021-2026)
Figure 72. Europe New Molecular Entities (NME) Drugs Sales Market Share by Type (2021-2026)
Figure 73. Europe New Molecular Entities (NME) Drugs Sales Market Share by Application (2021-2026)
Figure 74. Germany New Molecular Entities (NME) Drugs Revenue Growth 2021-2026 ($ millions)
Figure 75. France New Molecular Entities (NME) Drugs Revenue Growth 2021-2026 ($ millions)
Figure 76. UK New Molecular Entities (NME) Drugs Revenue Growth 2021-2026 ($ millions)
Figure 77. Italy New Molecular Entities (NME) Drugs Revenue Growth 2021-2026 ($ millions)
Figure 78. Russia New Molecular Entities (NME) Drugs Revenue Growth 2021-2026 ($ millions)
Figure 79. Middle East & Africa New Molecular Entities (NME) Drugs Sales Market Share by Country (2021-2026)
Figure 80. Middle East & Africa New Molecular Entities (NME) Drugs Sales Market Share by Type (2021-2026)
Figure 81. Middle East & Africa New Molecular Entities (NME) Drugs Sales Market Share by Application (2021-2026)
Figure 82. Egypt New Molecular Entities (NME) Drugs Revenue Growth 2021-2026 ($ millions)
Figure 83. South Africa New Molecular Entities (NME) Drugs Revenue Growth 2021-2026 ($ millions)
Figure 84. Israel New Molecular Entities (NME) Drugs Revenue Growth 2021-2026 ($ millions)
Figure 85. Turkey New Molecular Entities (NME) Drugs Revenue Growth 2021-2026 ($ millions)
Figure 86. GCC Countries New Molecular Entities (NME) Drugs Revenue Growth 2021-2026 ($ millions)
Figure 87. Manufacturing Cost Structure Analysis of New Molecular Entities (NME) Drugs in 2026
Figure 88. Manufacturing Process Analysis of New Molecular Entities (NME) Drugs
Figure 89. Industry Chain Structure of New Molecular Entities (NME) Drugs
Figure 90. Channels of Distribution
Figure 91. Global New Molecular Entities (NME) Drugs Sales Market Forecast by Region (2027-2032)
Figure 92. Global New Molecular Entities (NME) Drugs Revenue Market Share Forecast by Region (2027-2032)
Figure 93. Global New Molecular Entities (NME) Drugs Sales Market Share Forecast by Type (2027-2032)
Figure 94. Global New Molecular Entities (NME) Drugs Revenue Market Share Forecast by Type (2027-2032)
Figure 95. Global New Molecular Entities (NME) Drugs Sales Market Share Forecast by Application (2027-2032)
Figure 96. Global New Molecular Entities (NME) Drugs Revenue Market Share Forecast by Application (2027-2032)
Figure 1. Picture of New Molecular Entities (NME) Drugs
Figure 2. New Molecular Entities (NME) Drugs Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global New Molecular Entities (NME) Drugs Sales Growth Rate 2021-2032 (M Units)
Figure 7. Global New Molecular Entities (NME) Drugs Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. New Molecular Entities (NME) Drugs Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. New Molecular Entities (NME) Drugs Sales Market Share by Country/Region (2025)
Figure 10. New Molecular Entities (NME) Drugs Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Small Molecules
Figure 12. Product Picture of Monoclonal Antibodies
Figure 13. Product Picture of ADCs
Figure 14. Product Picture of Others
Figure 15. Global New Molecular Entities (NME) Drugs Sales Market Share by Type in 2026
Figure 16. Global New Molecular Entities (NME) Drugs Revenue Market Share by Type (2021-2026)
Figure 17. Product Picture of Oral Drugs
Figure 18. Product Picture of Injectable Drugs
Figure 19. Product Picture of Others
Figure 20. Global New Molecular Entities (NME) Drugs Sales Market Share by Administration Route in 2026
Figure 21. Global New Molecular Entities (NME) Drugs Revenue Market Share by Administration Route (2021-2026)
Figure 22. Product Picture of Receptor Agonists
Figure 23. Product Picture of Enzyme Inhibitors
Figure 24. Product Picture of Others
Figure 25. Global New Molecular Entities (NME) Drugs Sales Market Share by Action Mechanism in 2026
Figure 26. Global New Molecular Entities (NME) Drugs Revenue Market Share by Action Mechanism (2021-2026)
Figure 27. New Molecular Entities (NME) Drugs Consumed in Cancer Diseases
Figure 28. Global New Molecular Entities (NME) Drugs Market: Cancer Diseases (2021-2026) & (M Units)
Figure 29. New Molecular Entities (NME) Drugs Consumed in Immune Diseases
Figure 30. Global New Molecular Entities (NME) Drugs Market: Immune Diseases (2021-2026) & (M Units)
Figure 31. New Molecular Entities (NME) Drugs Consumed in Cardiovascular Diseases
Figure 32. Global New Molecular Entities (NME) Drugs Market: Cardiovascular Diseases (2021-2026) & (M Units)
Figure 33. New Molecular Entities (NME) Drugs Consumed in Others
Figure 34. Global New Molecular Entities (NME) Drugs Market: Others (2021-2026) & (M Units)
Figure 35. Global New Molecular Entities (NME) Drugs Sale Market Share by Application (2025)
Figure 36. Global New Molecular Entities (NME) Drugs Revenue Market Share by Application in 2026
Figure 37. New Molecular Entities (NME) Drugs Sales by Company in 2026 (M Units)
Figure 38. Global New Molecular Entities (NME) Drugs Sales Market Share by Company in 2026
Figure 39. New Molecular Entities (NME) Drugs Revenue by Company in 2026 ($ millions)
Figure 40. Global New Molecular Entities (NME) Drugs Revenue Market Share by Company in 2026
Figure 41. Global New Molecular Entities (NME) Drugs Sales Market Share by Geographic Region (2021-2026)
Figure 42. Global New Molecular Entities (NME) Drugs Revenue Market Share by Geographic Region in 2026
Figure 43. Americas New Molecular Entities (NME) Drugs Sales 2021-2026 (M Units)
Figure 44. Americas New Molecular Entities (NME) Drugs Revenue 2021-2026 ($ millions)
Figure 45. APAC New Molecular Entities (NME) Drugs Sales 2021-2026 (M Units)
Figure 46. APAC New Molecular Entities (NME) Drugs Revenue 2021-2026 ($ millions)
Figure 47. Europe New Molecular Entities (NME) Drugs Sales 2021-2026 (M Units)
Figure 48. Europe New Molecular Entities (NME) Drugs Revenue 2021-2026 ($ millions)
Figure 49. Middle East & Africa New Molecular Entities (NME) Drugs Sales 2021-2026 (M Units)
Figure 50. Middle East & Africa New Molecular Entities (NME) Drugs Revenue 2021-2026 ($ millions)
Figure 51. Americas New Molecular Entities (NME) Drugs Sales Market Share by Country in 2026
Figure 52. Americas New Molecular Entities (NME) Drugs Revenue Market Share by Country (2021-2026)
Figure 53. Americas New Molecular Entities (NME) Drugs Sales Market Share by Type (2021-2026)
Figure 54. Americas New Molecular Entities (NME) Drugs Sales Market Share by Application (2021-2026)
Figure 55. United States New Molecular Entities (NME) Drugs Revenue Growth 2021-2026 ($ millions)
Figure 56. Canada New Molecular Entities (NME) Drugs Revenue Growth 2021-2026 ($ millions)
Figure 57. Mexico New Molecular Entities (NME) Drugs Revenue Growth 2021-2026 ($ millions)
Figure 58. Brazil New Molecular Entities (NME) Drugs Revenue Growth 2021-2026 ($ millions)
Figure 59. APAC New Molecular Entities (NME) Drugs Sales Market Share by Region in 2026
Figure 60. APAC New Molecular Entities (NME) Drugs Revenue Market Share by Region (2021-2026)
Figure 61. APAC New Molecular Entities (NME) Drugs Sales Market Share by Type (2021-2026)
Figure 62. APAC New Molecular Entities (NME) Drugs Sales Market Share by Application (2021-2026)
Figure 63. China New Molecular Entities (NME) Drugs Revenue Growth 2021-2026 ($ millions)
Figure 64. Japan New Molecular Entities (NME) Drugs Revenue Growth 2021-2026 ($ millions)
Figure 65. South Korea New Molecular Entities (NME) Drugs Revenue Growth 2021-2026 ($ millions)
Figure 66. Southeast Asia New Molecular Entities (NME) Drugs Revenue Growth 2021-2026 ($ millions)
Figure 67. India New Molecular Entities (NME) Drugs Revenue Growth 2021-2026 ($ millions)
Figure 68. Australia New Molecular Entities (NME) Drugs Revenue Growth 2021-2026 ($ millions)
Figure 69. China Taiwan New Molecular Entities (NME) Drugs Revenue Growth 2021-2026 ($ millions)
Figure 70. Europe New Molecular Entities (NME) Drugs Sales Market Share by Country in 2026
Figure 71. Europe New Molecular Entities (NME) Drugs Revenue Market Share by Country (2021-2026)
Figure 72. Europe New Molecular Entities (NME) Drugs Sales Market Share by Type (2021-2026)
Figure 73. Europe New Molecular Entities (NME) Drugs Sales Market Share by Application (2021-2026)
Figure 74. Germany New Molecular Entities (NME) Drugs Revenue Growth 2021-2026 ($ millions)
Figure 75. France New Molecular Entities (NME) Drugs Revenue Growth 2021-2026 ($ millions)
Figure 76. UK New Molecular Entities (NME) Drugs Revenue Growth 2021-2026 ($ millions)
Figure 77. Italy New Molecular Entities (NME) Drugs Revenue Growth 2021-2026 ($ millions)
Figure 78. Russia New Molecular Entities (NME) Drugs Revenue Growth 2021-2026 ($ millions)
Figure 79. Middle East & Africa New Molecular Entities (NME) Drugs Sales Market Share by Country (2021-2026)
Figure 80. Middle East & Africa New Molecular Entities (NME) Drugs Sales Market Share by Type (2021-2026)
Figure 81. Middle East & Africa New Molecular Entities (NME) Drugs Sales Market Share by Application (2021-2026)
Figure 82. Egypt New Molecular Entities (NME) Drugs Revenue Growth 2021-2026 ($ millions)
Figure 83. South Africa New Molecular Entities (NME) Drugs Revenue Growth 2021-2026 ($ millions)
Figure 84. Israel New Molecular Entities (NME) Drugs Revenue Growth 2021-2026 ($ millions)
Figure 85. Turkey New Molecular Entities (NME) Drugs Revenue Growth 2021-2026 ($ millions)
Figure 86. GCC Countries New Molecular Entities (NME) Drugs Revenue Growth 2021-2026 ($ millions)
Figure 87. Manufacturing Cost Structure Analysis of New Molecular Entities (NME) Drugs in 2026
Figure 88. Manufacturing Process Analysis of New Molecular Entities (NME) Drugs
Figure 89. Industry Chain Structure of New Molecular Entities (NME) Drugs
Figure 90. Channels of Distribution
Figure 91. Global New Molecular Entities (NME) Drugs Sales Market Forecast by Region (2027-2032)
Figure 92. Global New Molecular Entities (NME) Drugs Revenue Market Share Forecast by Region (2027-2032)
Figure 93. Global New Molecular Entities (NME) Drugs Sales Market Share Forecast by Type (2027-2032)
Figure 94. Global New Molecular Entities (NME) Drugs Revenue Market Share Forecast by Type (2027-2032)
Figure 95. Global New Molecular Entities (NME) Drugs Sales Market Share Forecast by Application (2027-2032)
Figure 96. Global New Molecular Entities (NME) Drugs Revenue Market Share Forecast by Application (2027-2032)
